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Pneumocystis pneumonia (PCP) is an important opportunistic infection caused by the 
fungus Pneumocystis jirovecii. The incidence of PCP in sub-Saharan Africa is on the 
increase. This is due to the progression of the HIV-pandemic and limited access to health 
care facilities, specific highly active anti-retroviral therapy and chemoprophylaxis. It is a 
major cause of hospitalization and mortality in HIV-infected children with in-hospital 
case-fatality rates ranging from 20 – 63%.1-4 
The prevalence of PCP amongst HIV-infected South African children, hospitalized with
pneumonia, has been reported to vary from 10 – 49%.1-3 It is a common AIDS-defining
illness in infants in South Africa.1 Other risk factors for PCP in children, in addition to HIV
infection, include protein-energy malnutrition and HIV exposure. A Zambian post mortem
study found that 10% of children who died from PCP were HIV negative.5 HIV-exposed
children have been described to have a higher risk of PCP compared to unexposed
children. Recent reports describe probable transmission of P.jirovecii from an HIV-
infected mother to her HIV-exposed but uninfected infant.6,7 Despite the national roll-out
of the Prevention of Mother-To-Child-Transmission Programme in South Africa, many
HIV-infected or HIV-exposed children continue to be hospitalized for presumptive PCP
infection. Many of these children require admission into an intensive care facility.
When managing patients with suspected PCP, it is important to make an accurate 
laboratory diagnosis to confirm that Pneumocystis jirovecii is the cause of their lower 
respiratory tract infection. In HIV-infected patients, the differential diagnosis of diffuse 
pulmonary infiltrates, in addition to PCP, includes bacterial pneumonia and pulmonary 
tuberculosis. The case-fatality rate in children with untreated PCP approximates 100%,1-4 
making a rapid laboratory diagnosis essential in the management of these patients. A 
missed or an incorrect diagnosis may result in inappropriate treatment, which in addition 
to poor clinical outcomes, may have both cost implications and result in unnecessary 
adverse drug reactions. A rapid diagnostic test for PCP using non-invasive approaches for 
specimen collection will aid the laboratory diagnosis in resource-limited settings and 















The standard method for diagnosing PCP has been microscopic examination using Gomori 
Grocott’s methenamine silver nitrate stain which stain Pneumocystis cystic or sporocyte 
forms, or the more sensitive commercialized immunofluorescence (IF) tests to 
demonstrate the organism in respiratory samples. These tests have been used on 
bronchoalveolar lavage (BAL) or lung biopsy specimens in developed countries to 
diagnose PCP; however these methods of obtaining specimens are invasive, carry the risk 
of significant morbidity and mortality and are not routinely available in most developing 
countries. Sputum induction (IS) may be useful1-3 and nasopharyngeal swabs or aspirates 
(NPA) may yield P.jirovecii in severe infection3,4 . The combination of IS with NPA may 
provide a higher yield. Ruffini et al report a higher sensitivity of 70-80% when the results 
of both induced sputum and NPA were combined.3  
 
The development of DNA amplification by polymerase chain reaction (PCR) techniques, 
has provided a more sensitive and specific diagnostic method of detecting Pneumocystis 
in a variety of respiratory specimens, with the potential to improve diagnostic accuracy.8,9  
PCR may also prove useful for detection of P.jirovecii on specimens obtained using non-
invasive approaches from the upper airways including nasopharyngeal or oropharyngeal 
aspirates. In oral washes from HIV –positive patients, P.jirovecii DNA-amplification 
yielded a sensitivity of 70-80% using a standard PCR protocol compared with PCR on IS or 
BAL.8 This non-invasive procedure may reach 90% sensitivity when touch-down PCR is 
used. 8,9 This would be an advantage in children as the procedure risk is minimal and it is 
quick and simple to perform compared with sputum induction and BAL, which requires 
specialized equipment and expertise. In addition, serial non-invasive sampling can be 
performed in order to monitor response to therapy. In adults, PCR analysis of 
oropharyngeal aspirates may be useful for diagnosis but reported sensitivities have 
ranged from 40-80%.10,11 The efficacy of PCR for diagnosis of PCP in children, however, 
has not been well studied.  
 
In a study by Durand-Joly et al, patients with negative microscopy results but positive 
touch-down PCR on BAL but negative in oral washes, the absence of PCP was confirmed 














organism concerned. A positive PCR result with a low organism load may represent 
colonisation with P. jirovecii. Cut-off values representing the difference between 
colonization and infection has yet to be determined but will improve the specificity of the 
qualitative assay. 
 
Aims of the study 
 
 To establish a quantitative real-time PCR assay for the detection of P.jirovecii in 
respiratory samples based on a previously described method.12  
 
 To evaluate the performance of the real-time PCR assay for the detection of 
P.jirovecii in different clinical specimens in children with presumed PCP in 
comparison with the current standard method of immunofluorescence. We 
hypothesize that PCR is a more sensitive diagnostic method than 
immunofluorescence for the diagnosis of PCP in children. 
 
 To compare the performance of the PCR assay when performed on non-invasive 
nasopharyngeal aspirate samples with lower respiratory tract samples 
(bronchoalveolar lavage, induced sputum) from children with presumed PCP. We 
hypothesize that PCR on NPA samples will be more sensitive than 
immunofluorescence in the detection of P.jirovecii; and sensitivity and specificity of 
the assay on NPA samples may approach that of PCR performed on lower 
respiratory tract samples. 
Study population 
The study population comprises children (<14 years), admitted to the Red Cross 
Children’s War Memorial Hospital, with suspected PCP. Consecutive children, with a 
primary diagnosis of presumed PCP, will be prospectively enrolled. Induced sputum and 
NPA samples will be obtained, and non-directed BAL will be done in intubated children. 
The study will aim to enrol a minimum of 1 child per week over a 2-year period. 
 














 Acute onset (<2 weeks) of respiratory illness requiring hospitalization 
 Presence of tachypnoea (RR> 60 if less than 2 months, > 50 if less than a year, 
>40 if older than a year) 
 Hypoxia (room air saturation < 90%) 
 Diffuse bilateral lung disease, not associated with wheezing  
 One of the following risk factors for PCP: 
o HIV-infected or clinically suspected or 
o HIV-exposed or  
o Malnourished or 
o On immunosuppressive therapy or 
o Presence of immunodeficiency disease other than HIV 
 
Exclusion criteria will be treatment for PCP in the preceding 2 weeks, on PCP treatment 




The negative controls will consist of respiratory samples obtained for routine diagnostic 
purposes, from patients admitted to Red Cross Children’s War Memorial Hospital, that 
adhere to the following conditions: 
 
 Acute onset (<2 weeks) of respiratory illness, severe enough to warrant medical 
attention at a tertiary institute  
 Presence of respiratory compromise with or without hypoxia (room air 
saturation < 90%) 
 Presence or absence of HIV status or other co-morbidities 
 Has not been on treatment for PCP in the preceding 2 weeks or on PCP 
treatment for more than 48 hours prior to obtaining the specimen 
 Clinical improvement without being on treatment for PCP 
 Positive multiplex respiratory viral panel PCR performed on appropriate 














The clinical records of patients, who have had routine respiratory specimens submitted, 
will be reviewed in order to collect the above information. The samples will be made 
anonymous prior to analysis so that the results cannot be linked back to individual 
patients. 
Investigations 
Nasopharyngeal aspirates representing upper respiratory tract specimens and induced 
sputum or bronchoalveolar lavage fluid from the lower respiratory tract will be submitted 
for detection of P. jirovecii by:  
 
o Immunofluorescence  
Direct immunofluorescence (Detect IF, Axis-Shield Diagnostics, UK) using a monoclonal 
antibody will be performed on sputum, NPA and BAL specimens to detect P. jirovecii. This 
is the currently employed standard diagnostic test to d tect PCP in patients admitted to 
Groote Schuur Hospital and Red Cross Hospital. 
 
o Silver stain 
Grocott’s methenamine silver nitrate stain will be performed by the Cytology Department 
at Red Cross Hospital on certain of the trial BAL specimens, as per clinicians request. The 
results we be used as part of our analysis.  
 
o PCR  
 
The study will be conducted at the National Health Laboratory Service (NHLS) 
laboratories at Groote Schuur Hospital. All work will be performed in an ISO-accredited 
molecular laboratory, which employs strict precautions to prevent contamination. The 
investigators performing PCR methods will be blinded to the immunofluorescence 















Specimens will be stored at -70ºC. The PCR assay will be carried out as described below 
with standards for quantification, a positive control (DNA extracts of a known P. jirovecii 




Deoxyribonucleic acid extraction 
DNA will be extracted from using the NucliSENS Magnetic Extraction kit (bioMerieux) in 
accordance with the manufacturer’s recommendation. These will be performed on the 
NucliSENS easyMAG platform.  
 
Quantitative real-time PCR 
P. jirovecii DNA will be detected using a quantitative, touch-down, real-time PCR assay 
targeting the major surface glycoprotein (MSG) gene based on the publication by Larsen 
et al. This assay has been shown to be as sensitive as the nested PCR assay, but more 
specific.9 
 
Tenfold serial dilutions of a cloned target will be used as standards for quantification. The 
P.jirovecii MSG gene has been cloned into the pCR 2.1 vector and this has been donated 
to us by J. Kovacs M.D. (NIH). The plasmid will be propagated in E.coli competent cells 
using a standard transformation protocol and will be purified using the QIAGEN Plasmid 
Midi Kit (QIAGEN). Deoxyribonucleic acid concentration will be evaluated and tenfold 
serial dilutions will be prepared as standards for quantification 
 
MSG primers which have been commercially synthesized, JKK14/15 (5_-GAA TGC AAA TCY 
TTA CAG ACA ACA G-3_) and JKK17 (5_-AAA TCA TGA ACG AAA TAA CCA TTG C-3_),12 
which amplify a 250-bp segment of the multicopy MSG gene family, will be obtained for 
use in the assay. Fluorescence resonance energy transfer (FRET) probes designed as per 
publication by Larsen et al. will be used for detection. 12 The assay will be performed on 
the. Lightcycler platform (Roche) and each PCR reaction will have a final volume of 20ul. 
The assay conditions utilised will be based on those used by Larsen et al.12 Each run will 














external standard curve required for quantification of any positive patient samples that 
might appear in the run. Fluorescence measurements will be analysed using the 
Lightcycler software 
 
External controls: A sample with a positive immunofluorescence result will be included as 
a positive control in addition to the cloned target being used as standards for 
quantification. A negative extraction control will also be included in each PCR run. 
 
Specificity studies: Respiratory samples from 25 patients with respiratory symptoms 
similar to PCP, who have improved clinically without treatment targeted against 
P.jirovecii, will be analyzed as a control group. 
 
o Other investigations  
Routine laboratory investigations will be done on respiratory specimens including 
immunofluorescence for P. jirovecii, bacterial culture, microscopy and culture for 
Mycobacterium tuberculosis and viral detection, as indicated clinically. Other 
investigations will be at the discretion of the attending physician. 
Treatment 
All patients with suspected PCP will be treated empirically according to the hospital’s 
standard guidelines. This will include intravenous Cotrimoxazole (TMP-SMX), 
corticosteroids and a broad-spectrum antimicrobial agent. The decision to admit to an 
intensive care unit facility will be at the discretion of the attending doctor. 
Analysis  
 
The performance of the PCR assay will be assessed by determining the sensitivity and 
specificity of the test. The result of each PCR reaction on a specific patient sample will be 
compared to the corresponding immunofluorescence result (and silver stain result, if 
available). The PCR results of the nasopharyngeal aspirates will be compared to the 
results obtained from the lower respiratory tract sample types, namely induced sputa 














be made using a chi square test. If the child is discharged from medical care or dies or for 




 To optimise and validate the use of a quantitative PCR assay for detection of P. 
jiroveci in respiratory samples. 
 To evaluate the usefulness of the direct immunofluorescence test compared to 
that of PCR on respiratory samples from patients with presumed PCP. 
 To describe the value of real-time PCR on non-invasive nasopharyngeal aspirate 





With the rising HIV-pandemic in South Africa, the ability to offer a rapid, reliable, 
diagnostic test for Pneumocystis could prove clinically invaluable. PCR could gain 
acceptance as the standard technique available for the diagnosis of PCP. 
 
If the quantitative, touch-down, real-time PCR assay proves to be a sensitive and specific 
diagnostic test, as anticipated, it would be possible to offer the test to institutes other 
than Groote Schuur Hospital and Red Cross Hospital. It would also be offered for testing 
in adult patients. This would further enhance and expand the repertoire of molecular 
diagnostics offered at our laboratory. 
 


















Caveats and potential limitations 
 
1. Contamination may result in false positives. The molecular laboratory layout 
ensures strict separation of the extraction and amplification steps. Aerosol-barrier 
pipette tips will be used in steps involving reagent transfer in the PCR process. The 
design of this PCR method should, however, carry a lower risk of contamination as 
the assay is performed in a closed system with limited manipulation of PCR 
products. Quality control measures will include relevant positive and negative 
controls in each PCR run. 
 
2. If the patient sample obtained is inadequate for all microbiological investigations 
requested by the attending clinician, then only the current standard diagnostic 
method (IF) will be performed. Some patients may only be able to provide one 
respiratory sample, however this will still be included in the analysis.  
 
3. In asymptomatic patients, particularly those that are immunocompromised, the 
relevance of a positive PCR result is not known. A positive result may represent 
colonisation or sub-clinical infection and the decision on whether or not to treat 
the patient, can be difficult. This real-time PCR method allows for quantification 
and therefore the dete mination of organism load or concentration per microlitre 
of sample. Patients with infection will have a higher organism load than patients 
that are colo ised. Determining the cutoff values representing the difference 
between colonization versus infection may, however, prove to be challenging but 
will improve the specificity of the qualitative assay. 
 
4. Currently there is no known ideal gold standard for the laboratory diagnosis of 
PCP. Most clinicians treat empirically if clinical symptoms and signs and 
radiological evidence suggests PCP. Culture is not possible and the poor 
performance of microscopy means that a positive result is confirmatory however 
a negative result cannot exclude the presence of PCP. It is, therefore, not possible 
to accurately determine the sensitivity of our PCR assay as we currently have no 














to distinguish between clinical true and false positivity and thereby improve the 
sensitivity of the assay. 
Ethics  
 
The patient samples that shall be obtained during the study will most often form part of 
the routine diagnostic work-up on the patient to exclude bacterial, fungal and viral 
infections. If additional study-specific samples need to be taken in order to obtain patient 
sample pairs, it most commonly will be a nasopharyngeal aspirate. The investigation is 
considered to be a low-risk procedure and shall not result in the deterioration in the 
patient’s respiratory condition.       
 
Informed consent will be obtained from a parent or legal guardian prior to inclusion into 
the study. The study conduct will adhere to the Declaration of Helsinki 2008. 13 
 
The study will commence after approval from the Department of Clinical Laboratory 
Science and the Ethics Committee at the University of Cape Town. 
 
Funding has been approved and will be provided by the NHLS Research Trust. 
 
This study forms part of a larger collaborative study involving clinicians at Red Cross 
Children’s Hospital and the NHLS Laboratory. Further objectives to be included in the 
larger clinical study will be to:  
 To determine the prevalence of mutations in the P jirovecii DHPS gene in South 
African children and to investigate whether the presence of mutations is associated 
with disease severity, prior TMP-SMX exposure or treatment failure  
 To investigate the epidemiology of resistant P jirovecii isolates over time  
 To investigate the serological responses to pneumocystis antigens in children with 
PCP. 
 
Both institutional approval (Institute of Child Health) and UCT Research Ethics Committee 
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PART B: LITERATURE REVIEW 
 
Objectives of the literature review 
 
The objective of this literature review was to describe and evaluate current tests used for 
the detection of Pneumocystis jirovecii in different clinical specimens in children with 
presumed pneumocystis pneumonia (PCP) and to identify areas where further research 
may be needed, particularly in the context of diagnosis in resource-limited settings. In 
order to achieve this it was also necessary to review (1) the incidence of PCP in HIV-
infected South African children; (2) the prevalence of the condition amongst HIV-infected 
South African children hospitalized with pneumonia; (3) the mortality in children 
hospitalized with PCP and (4) risk factors, other than HIV, associated with the 
development of PCP infection. 
 
Literature search strategy 
 
The literature search was performed using PubMed which comprises biomedical 
literature from MEDLINE, life science journals, and online books, all up to November 
2008. The following search string was used to identify studies: (Pneumocystis [medical 
subject headings {MeSH}] OR Pneumonia, Pneumocystis [MeSH] OR Pneumocystis 
Infections [MeSH] OR Pneumocystis carinii [MeSH] OR Pneumocystis jirovecii [MeSH] OR 
pcp) AND (diagnosis [Subheading] OR immunofluorescence [MeSH]) OR PCR [MeSH] OR 
real-time OR molecular diagnosis. General search terms were then replaced with more 
specific ones (eg. incidence, nasopharyngeal aspirate, bronchoalveolar lavage, induced 
sputum) and additional terms were added to the search (e.g. HIV). Citations were limited 
by age group (all children: 0-18 years), language (to sources in the English language) and 
the search was confined to human studies. Due to the paucity of studies, especially in 
Africa, looking at the incidence of PCP and new diagnostics, no limit was applied to 
publication date or geographical specificity and therefore both local and international 
data were included in the review. References of identified studies were further inspected 















This review included studies that prospectively and retrospectively investigated the 
incidence of PCP in HIV-infected children as well as studies that assessed patient 
mortality and that described risk factors for the condition. Studies comparing a diagnostic 
test with a reference standard or studies that compared the performance of the same 
diagnostic test on a variety of clinical specimens were included. Patient populations in 
these diagnostic studies included those with known risk factors for acquiring the 
infection, such as those with cancer, on immunosuppressive therapy or prolonged 
corticosteroid treatment, those receiving solid organ or bone marrow allografts and 
children with protein-energy malnutrition. 
 
Summary of the literature 
 
Introduction 
Pneumocystis pneumonia (PCP) is an important opportunistic infection caused by the 
fungus Pneumocystis jirovecii. The organism was discovered in 1909 by Chagas, but the 
cystic forms were mistakenly considered to be part of the trypanosome life cycle. It was 
named Pneumocystis carinii (Greek: pneumon ‘lung’, kystis ‘cyst’) after Antonio Carini in 
1912 (Dail et al., 2008). Prior to 1988, the organism was considered to be a protozoan. 
The controversy regarding its taxonomy and classification continued for decades and 
recently, based on ribosomal RNA sequences homologous to that found in fungi, it was 
re-classified as a fungus. Advances in molecular technology led to 5 species being 
described with P. carinii and P. wakefieldiae described as infecting strains in rats 
(Gigliotti, 2005). 
 
Pneumocystis organisms infecting humans were re-named P. jirovecii in 1999, in honor of 
Otto Jirovec, who described Pneumocystis pneumonia in humans in 1952 (Dail et al., 
2008). P. jirovecii infection is well known to cause interstitial plasma cell pneumonia, 
primarily in immune-compromised patients. The incidence seems to be on the increase in 
sub-Saharan Africa due to the progression of the HIV-pandemic and limited access to 
health care facilities, specific highly active anti-retroviral therapy and chemoprophylaxis. 
It has been considered an under-diagnosed condition due to the difficulties in diagnosing 
















In a Zimbabwean post-mortem study of children who died at home, PCP was found in 
16% of children found to be HIV-positive (Ikeogu et al., 1997). A study in Côte d’Ivoire 
reported PCP in 23% of HIV-positive children during necropsy studies performed on 
children who died in the community or at hospital prior to a clinical diagnosis being made 
(Lucas et al., 1996). However, the occurrence of PCP in HIV-infected infants and children 
in Africa was largely unavailable until Zar et al. (2000) conducted the first large, 
prospective study to investigate the incidence of PCP in HIV-infected children with 
pneumonia in Cape Town, South Africa. In this study, PCP accounted for 10% of acute 
pneumonia episodes in hospitalized HIV-infected children and was the AIDS-defining 
infection in 20% of those newly diagnosed as HIV-positive. This figure was probably an 
underestimate however, as the diagnosis was made by microscopy of induced sputum in 
most subjects and not on bronchoalveolar lavage samples, as the study was performed in 
a resource-poor setting.  In another study, Zar et al. (2001) showed that in HIV-infected 
children admitted to intensive care in a developing country, 38% had evidence of PCP on 
induced sputa and non-directed BAL samples from intubated patients.  
 
PCP is considered a major cause of mortality in HIV-infected children and in-hospital case-
fatality rates range from 20 – 63% (Madhi et al., 2002; Ruffini et al., 2002; Graham et al., 
2000). In Zar’s study in 2000, 7 of 15 (47%) children with PCP died while hospitalized 
compared with 24 of 136 (18%) without PCP [RR 1.21 (0.99 - 1.47)] (Zar et al., 2000). In 
the 2001 study of patients admitted to intensive care, 31 of 151 (20%) HIV-positive and 8 
of 99 (8%) HIV-negative children died [RR 1.16 (95% CI 1.05-1.28), p=0.008] and using 
multiple logistic regression, PCP was the only risk factor for mortality (p = 0.03) (Zar et al., 
2001). 
 
In addition to HIV infection, other risk factors identified for PCP in children include 
protein-energy malnutrition and HIV exposure (Ikeogu et al., 1997; Su et al., 2008). In a 
Zambian post mortem study, Chintu (2002) found that 7% of children who died from PCP 
were HIV negative. All these children were identified as being less than six months of age 














have been described to have a higher risk of PCP compared to unexposed children, which 
may be due to transmission of P. jirovecii from an HIV-infected mother to her HIV-
exposed but uninfected infant (Heresi et al., 1997; McNally et al., 2005). 
 
Despite the national roll-out of the Prevention of Mother-To-Child-Transmission (PMTCT) 
Programme in South Africa, many HIV-infected or HIV-exposed children continue to be 
hospitalized for presumptive PCP infection (Morrow et al., 2010). Management of these 
patients with suspected PCP ideally includes making an accurate laboratory diagnosis to 
confirm P. jirovecii as the cause of their lower respiratory tract infection. This is essential 
in HIV-infected patients, as the differential diagnosis of diffuse pulmonary infiltrates is 
broad and in addition to PCP, includes viral and bacterial pneumonia, and pulmonary 
tuberculosis, the management and prognosis of which varies depending on the infection. 
 
Diagnosis 
The current gold standard test most commonly used for diagnosing PCP is microscopy 
using either the Gomori methenamine silver nitrate stain which stains Pneumocystis 
cystic and sporocyte forms, or the commercial (direct fluorescent-antibody) 
immunofluorescence (IF) assay (Caliendo et al., 1998). Other conventional tests available 
that morphologically demonstrate the organisms in respiratory specimens include Giemsa 
or Giemsa-like rapid stains (e.g. Diff-Quik) and the toluidine blue O stain. Of all these 
microscopy methods, immunofluorescence has the advantage of requiring less time, 
fewer reagents and may be the most sensitive (Kovacs et al., 1988). A major limitation to 
the use of immunofluorescence is the need for a fluorescent microscope, as well as, 
experienced microscopists. Valerie (1990) examined a variety of respiratory specimens 
from known or suspected HIV-infected patients with modified Giemsa and IF stains. The 
organism was detected in 92% of the specimens using the modified Giemsa and in 97% of 
the specimens by use of the fluorescent-antibody stain. 
 
Microscopy is usually performed on bronchoalveolar lavage (BAL) fluid obtained via 
fiberoptic bronchoscopy or on lung biopsy specimens (transbronchial biopsy or open-lung 
biopsy) in developed countries (Nyamande et al., 2005). However, obtaining these 














lavages in sick infants may cause deterioration in the respiratory status of the child 
(Morrow et al., 2004). In addition these techniques require expertise and specialized 
equipment which may not be available in resource-limited settings. This form of diagnosis 
is thus not routinely available in most developing countries and many patients may be 
treated empirically without a laboratory-confirmed diagnosis. 
 
Less invasive approaches to obtaining respiratory specimens from children include 
sputum induction (IS) and nasopharyngeal swabs or aspirates (NPA). Sputum induction 
has been reported as useful by Zar (2000), Madhi (2002) and Ruffini (2002) when 
compared to the above-mentioned reference methods of BAL or lung biopsy. Silver stain 
had a similar sensitivity whether used on IS or BAL (Pinlaor et al., 2004). 
 
Examination of NPA specimens may yield P. jirovecii in severe pulmonary infection as 
shown by Ruffini (2002). The sensitivity and specificity of microscopy on a combination of 
induced sputum and NPA were 75% and 80% respectively, as compared to post-mortem 
lung histology. The ability to detect P. jirovecii in NPA samples may be due to the high 
organism load in the respiratory tract in severe disease or the fact that the organisms 
may reach the upper airways during the process of coughing. However, not all studies 
have found examination of NPA samples useful. Zar et al. (2000) using IF found no 
positive results on NPA samples in a group of 15 children, 9 of which were positive by 
examination of IS and 6 positive by examination if BAL fluid.  
 
Molecular diagnostics 
The advent of molecular technology has revolutionized laboratory diagnostics. Nucleic 
acid amplification techniques, such as polymerase chain reaction (PCR), have provided 
more sensitive and specific diagnostic methods to detect P. jirovecii (Nyamande et al., 
2005; Brancart et al., 2005; Fischer et al., 2001; Flori et al., 2004; Larsen et al., 2002; 
Palladino et al., 2001). Commonly used target genes in conventional nested PCR include 
the mitochondrial large subunit ribosomal RNA (mtLSU rRNA) and the internal transcribed 
spacer (ITS) region and the dihydropteroate synthase (DHPS) gene (Helweg-Larsen et al., 
1997; 1998; Ribes et al., 1997; Olssen et al., 2001 Flori et al., 2004; Gupta et al., 2008; Su 














al., 2006) and more recently the multicopy major surface glycoprotein (MSG) gene of P. 
jirovecii has improved the performance of real-time assays as discussed below (Larsen et 
al., 2002; Larsen et al., 2004). 
 
As with microscopy, PCR assays have been used on both lower and upper respiratory 
tract samples. The motivation for these studies was that if PCR had good sensitivity and 
specificity in oropharyngeal washings, it could be a useful substitute in situations where 
sputum induction or fiberoptic bronchoscopy is either unavailable or contraindicated. The 
utility of DNA amplification to detect P. jirovecii in oropharyngeal washes in adult patients 
was described by Wakefield (1993) who reported a sensitivity of 56% in comparison to 
microscopy with methenamine silver staining of bronchoscopic lavage samples. A similar 
study in Kwa-Zulu Natal (Nyamande et al., 2005) assessed the diagnostic utility of PCR as 
a rapid screen for P. jirovecii DNA in non-invasive oropharyngeal samples from adult 
patients and compared their results to the gold standards of histology and microscopy on 
BAL fluid, unlike Wakefield et al. (1993) who only compared their results to microscopy 
on BAL. The sensitivity of DNA amplification using oropharyngeal washes in this study was 
found to be 44% and 40% (Nyamande et al., 2005). Prior to this, no study had compared 
the sensitivity and specificity of PCR on oropharyngeal washes to histology of BAL fluid. 
 
Nyamande’s study showed that the use of primers targeting the gene encoding the large 
subunit mitochondrial ribosomal RNA of P. jirovecii had a low sensitivity and specificity 
when compared with microscopy on lung tissue or microscopy on BAL fluid. The 
questions raised by these results are whether the target was appropriate, or whether 
oropharyngeal washes are actually poor specimen types for detection of P. jirovecii. 
There are other genetic loci for which PCR primers are available which may have given 
better results. The conclusion drawn from this study was that PCR is still useful and that 
refinements to the methods of sample collection, storage, and laboratory techniques may 
result in higher sensitivities.  
 
Another study using a standard nested PCR protocol targeting the mitochondrial 23S 
rDNA region of P. in oral washes from HIV-positive adult patients, yielded a sensitivity of 














or dot-blot hybridization applied to BAL samples, which is usually higher than 95% 
(Tamburrini, et al. 1998), indicating that both the amplification method as well as the 
method of detecting amplification products, plays a large part in determining the 
performance of the PCR assay. 
In 2004, Larsen et al. used a quantitative touch-down PCR assay targeting the multicopy 
major surface glycoprotein (MSG) gene of P. jirovecii on oral-wash samples from HIV-
infected adults to demonstrate a sensitivity of 88% and a specificity of 85%. He compared 
this to direct microscopy of induced sputum or BAL by use of Diff-Quik (Dade Behring) 
and concluded that PCR of oral-wash samples can be an accurate and noninvasive 
method for diagnosis of PCP. Touch-down PCR is a method by which primers avoid 
amplifying non-specific sequences by the use of higher annealing temperatures, above 
the projected melting temperature. The annealing temperature is decreased by 1°C every 
cycle until a “touchdown” annealing temperature is reached. This specific touchdown 
temperature is subsequently used for the remaining cycles (Larsen et al., 2002). 
 
Alvarez-Martinez (2006) reported a sensitivity as high as 90% using touch-down PCR. In 
this study, both nested and quantitative real-time PCR methods for the amplification of 
the P. jirovecii dihydropteroate synthase (DHPS) gene were evaluated using a variety of 
stored clinical lower respiratory samples from children and adults in Spain, South Africa, 
and Brazil. The sensitivities of both assays was high, ranging from 62.5 - 100% depending 
on the type of specimen that was analyzed. In a subset of 71 microscopically confirmed 
PCP cases and 70 negative cases, there was no significant differences in sensitivity 
between real-time and nested PCR (both were 94%), however, the specificity of real-time 
PCR was significantly higher than that of nested PCR (96% vs. 81%; p = 0.015). The 
carryover problem in nested PCR could perhaps explain the high number of false-positive 
results and this risk of contamination and consequently lower specificity is one of the 
most important problems of nested PCR. Real-time PCR methods offer other advantages 
in addition to decreased contamination rates, such as rapidity and dynamic detection. In 
this study, the results were reported as being obtained in less than 3 hours compared 















The issue of Pneumocystis colonization has recently been a topic of interest. Colonization 
may be defined as isolation of a microbe that does not result in sufficient damage to 
cause clinical disease but that may alter host homeostasis (Calderon et al., 2010). For 
Pneumocystis, in particular, colonization may be the explanation when there is detection 
of the organism or its DNA in respiratory samples from individuals who do not have signs 
or symptoms of pneumonia. Among adults, Pneumocystis colonization has been 
demonstrated in both HIV-infected and non–HIV-infected individuals. Certain groups 
appear to have a higher risk of colonization. These include, older individuals who do not 
have predisposing illnesses, and those who are not immunosuppressed but have chronic 
lung disease. These colonized individuals may be a major species-specific reservoir of 
infection (Maskell et al., 2003; Calderon et al., 2010) 
 
In the study by Durand-Joly (2005), patients with negative microscopy results, positive 
touch-down PCR on BAL and negative PCR in oral washes, the absence of PCP was 
confirmed clinically and colonization was concluded. Since real-time PCR allows for 
quantification of the organism, it may be possible to differentiate colonization from 
infection based on organism load.  Larsen et al. (2002) developed a rapid (time to 
completion <4 hours, including DNA extraction), quantitative touch-down real-time assay 
to study this.  The assay utilized an associated internal control and fluorescence 
resonance energy transfer (FRET) probes for detection. The touch-down procedure 
significantly increased the sensitivity of the assay compared to a non-touch-down 
procedure. P. jirovecii DNA was detected in respiratory specimens from patients with PCP 
and from patients without clinical evidence of PCP. These latter patients were thought to 
be either colonized or to have subclinical infection. They hypothesized that quantification 
might prove helpful in distinguishing between infected and colonized patients: the latter 
group would have lower copy numbers than patients with PCP. A blinded, retrospective 
study of 98 respiratory samples (49 lower respiratory tract specimens and 49 oral 
washes), from 51 patients with 24 episodes of PCP and 34 episodes of other respiratory 
disease, was conducted. PCR-positive samples from colonized patients contained lower 
concentrations of DNA than samples from PCP patients. The data obtained from that 
study suggested that this quantitative PCR could be used to determine if P. jirovecii is 














infection. Cut-off values representing the difference between colonization and infection 
would therefore improve the specificity of the assay. Unfortunately, no reliable cut-off 
values have been determined to date. 
 
Problems identified and the need for further research 
 
The analysis had a number of limitations. Many of the studies were not clinically up to 
date but were included because of the paucity of literature on the subject of incidence 
and diagnostics. The true incidence of PCP in South Africa may have increased with the 
progression of the HIV-pandemic and limited access to health care facilities or decreased 
since the advent of PMTCT and the wider use of chemo-prophylaxis. 
 
One problem in many of the earlier trials was the use of different microscopic methods, 
performed in different laboratories, as the “gold standard”, making comparisons 
between studies difficult. The different staining methods themselves could have varying 
sensitivities and specificities. In addition, the reference standards previously used did not 
have high sensitivities. 
 
Methodological issues also arose. Some studies may not have been adequately powered 
to determine significant differences between tests. Logistical problems such as storage, 
freezing, and thawing of samples or poor calibration of equipment may have affected the 
accuracy of some of the diagnostic tests. Several factors also threatened the internal and 
external validity of the studies. Some of these factors had to do with the design of the 
studies, others with the selection of patients, the execution of the tests, or the analysis of 
the data. When analyzing the results of these diagnostic studies, the possibility for bias 
had to be considered, specifically, publication bias where there seemed to be the 
preferential publication of studies that show improved detection of PCP infection versus 
those that show no effect.  
 
In conclusion, PCP is a common AIDS-defining infection in infants in South Africa, with a 
high case fatality rate in children with untreated PCP. A rapid laboratory diagnosis is thus 














invasively collected specimens would facilitate the laboratory diagnosis in resource-
limited settings and allow early initiation of appropriate treatment, thereby improving 
patient outcome. Although sputum induction has been successfully used to diagnose PCP 
in HIV-infected adults using microscopy, this technique has not commonly been used in 
children and not diagnostically evaluated in infants. Use of less invasive samples, such as 
nasopharyngeal aspirates would be an advantage in children as the procedure risk is 
minimal and it is quick and simple to perform compared with sputum induction and BAL, 
which requires specialized equipment and expertise. In adults, PCR analysis of 
oropharyngeal aspirates has been described as useful for diagnosis although reported 
sensitivities range from 40-80%. The efficacy of PCR for diagnosis of PCP in children, 
however, has not been well studied. Data from developed countries indicate that the 
peak incidence of paediatric PCP occurs before 1 year of age. Further trials are thus 
needed in a representative paediatric population using methodology and techniques that 
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Background: Pneumocystis pneumonia (PCP) is a major cause of hospitalization and 
mortality in HIV-infected children in Africa. Diagnosis relies predominantly on silver or 
immunofluorescent staining of a lower respiratory tract specimen, which may be difficult 
to obtain. 
  
Objectives: (1) To compare the diagnostic yield of PCR with immunofluorescence (IF) and 
(2) to investigate the usefulness of upper compared to lower respiratory tract samples for 
diagnosing PCP in children. 
 
Methods: Children hospitalised at an academic hospital with suspected PCP were 
prospectively enrolled between November 2006 and August 2008. An upper respiratory 
sample (nasopharyngeal aspirate, NPA) and a lower respiratory sample (induced sputum, 
IS or bronchoalveolar lavage, BAL) were submitted for real-time PCR and direct IF for the 
detection of Pneumocystis jirovecii. 
 
Results: 202 children (median age 3.3 [interquartile range, IQR 2.2 - 4.6] months) were 
enrolled. The overall detection rate by PCR was higher than by IF [180/349 (52%) vs. 
26/349 (7%) respectively; p<0.0001]. PCR detected more infections compared to IF in 
lower respiratory tract samples [93/166 (56%) vs. 22/166 (13%); p<0.0001] and in NPAs 
[87/183 (48%) vs. 4/183 (2%); p<0.0001]. Detection rates by PCR on upper (87/183; 48%) 
compared with lower respiratory tract samples (93/166; 56%) were similar (OR, 0.71; 95% 















Conclusion: Real-time PCR is more sensitive than IF for the detection of P. jirovecii in 
children with PCP. NPA samples may be used for diagnostic purposes when PCR is 
utilised. Wider implementation of PCR on NPA samples is warranted for diagnosing PCP in 
children. 
 



































Pneumocystis pneumonia (PCP), caused by Pneumocystis jirovecii, is an important 
opportunistic infection in HIV-infected children. [1, 2] The incidence of PCP in developed 
countries has declined since the introduction of highly active anti-retroviral therapy and 
use of chemoprophylaxis. However, PCP remains a major cause of hospitalization and 
mortality in HIV-infected children in low or middle income countries, [1, 3-5] with 
reported incidence rates of 10 – 49%, [1, 3, 6] and in-hospital case-fatality rates of 20 – 
63%. [1, 3-4, 6] Apart from HIV infection, there are other factors that predispose children 
to developing PCP including malnutrition, other immune deficiencies or HIV exposure. 
Untreated, the case fatality rate in children with PCP approximates 100%. [1, 3-4, 6] 
However, the diagnosis can be difficult as clinical and radiological findings are non-
specific. Therefore, a rapid, accurate laboratory diagnosis is important for timely use of 
appropriate medication. 
 
Detection of P. jirovecii is hampered by the lack of a sustainable in-vitro culture method. 
[7] Standard laboratory diagnostic methods are microscopic examination of a lower 
respiratory tract sample with Gomori Grocott’s methenamine silver nitrate stain or the 
more sensitive immunofluorescence assay (IF) [8] on bronchoalveolar lavage (BAL) or 
induced sputum (IS) specimens. Using microscopy, the yield from IS has been reported to 
be similar compared to that from BAL. [9] However, sputum induction in children is not 














deterioration or nosocomial transmission of respiratory pathogens. Diagnosis using a 
non-invasive sample such as a nasopharyngeal aspirate (NPA) is, therefore, desirable. 
 
The clinical sensitivity from a NPA has been reported to be low and variable when 
microscopy is utilised. [4-5, 10] The development of polymerase chain reaction (PCR) 
techniques has provided a more reliable diagnostic method. In adult studies, PCR is as 
specific and more sensitive than microscopy for diagnosis, when performed on 
respiratory specimens, including oral washes. [7, 9, 11-20] In a study of oropharyngeal 
washes from HIV-infected adult patients, P.jirovecii DNA-amplification had a sensitivity of 
44% using a nested PCR protocol compared to trans-bronchial biopsy, [15] increasing to 
90% when touch-down real-time PCR was utilised. [7, 9] Real-time PCR also allows for 
quantification of the organism load and with application of cutoff values, could improve 
the specificity by distinguishing between colonization and infection. [12] 
 
The aims of this study were (1) to compare a real-time quantitative PCR assay with IF for 
the diagnosis of PCP in children and (2) to evaluate the reliability of PCR for the diagnosis 
























Consecutive children (<14 years old) with suspected PCP, hospitalized at Red Cross War 
Memorial Children’s Hospital, Cape Town, South Africa,  were enrolled from  November 
2006 to August 2008. Clinical criteria for suspected PCP were an acute onset of a 
respiratory illness, presence of age-specific tachypnoea and hypoxia, bilateral lung 
disease (not associated with wheezing) and a risk factor for PCP (HIV-infected, HIV-
exposed, malnourished, receiving immunosuppressive therapy or immunodeficiency 
disease other than HIV). Patients were excluded if they had received treatment for PCP 
in the preceding 2 weeks or were on PCP treatment for more than 48 hours. A child was 
defined as HIV-infected if they had a positive HIV PCR (Amplicor HIV-1 DNA test version 
1.5, Roche Diagnostics GmbH, Mannheim, Germany) if younger than 18 months or a 
positive HIV ELISA (Architect HIV Ag/Ab Combo ELISA, Abbott Laboratories, Abbott Park, 
IL) in older children. HIV exposure in infants less than 18 months was defined as being 
HIV seropositive with a negative HIV PCR. All children were treated according to a 
standard protocol for severe pneumonia that included intravenous cotrimoxazole and 
oral corticosteroids, as well as broad-spectrum antibiotics. Other antimicrobial therapy 
was added at the discretion of the attending clinician. Written informed consent was 
obtained from a parent or legal guardian.   The study was approved by the Research 


















An upper respiratory tract sample (NPA) and a lower respiratory tract sample (IS in non-
intubated patients or BAL in intubated patients) were obtained using standardised 
methods. [10, 21] After routine laboratory investigations had been performed, an aliquot 
of sample was frozen at -70°C for analysis by PCR. 
 
Control group 
Respiratory samples (NPA or BAL) from 30 children hospitalized with a confirmed viral 
lower respiratory tract infection, and who improved clinically without specific treatment 
for PCP, were investigated with PCR for PCP, as a control group. 
 
Laboratory investigations 
Direct immunofluorescence (IF) (Detect IF PC, Axis-Shield Diagnostics, Cambridgeshire, 
United Kingdom) to detect P. jirovecii using a monoclonal antibody immunofluorescent 
stain was performed according to the manufacturer’s instructions. In addition, Grocott’s 
methenamine silver nitrate stain was performed on BAL specimens, as per clinician’s 
request, if sufficient sample volume was available.  
 
DNA was isolated using the Nuclisens EasyMAG platform (bioMérieux, Boxtel, 
Netherlands). P. jirovecii DNA was detected using a quantitative, touch-down, real-time 
PCR assay, targeting the major surface glycoprotein (MSG) gene as described by Larsen 
et al. [12] Commercially synthesized primers, amplifying a 250-bp segment of the 
multicopy MSG gene family, were utilized in a PCR reaction containing fluorescence 














The P. jirovecii MSG gene was cloned into the pCR 2.1 vector. Four external standards of 
the cloned target template, corresponding to 106, 105, 104 and 103 copies per microlitre, 
were used in each PCR run to generate an external standard curve, required for 
quantification. The reactions were performed on the LightCycler platform (Roche 
Diagnostics GmbH, Mannheim, Germany) and results were calculated using the 
LightCycler software and expressed in copies/mL. A P. jirovecii positive and a negative 
control were included in each PCR run. Laboratory testing was conducted in an ISO-
accredited molecular laboratory of the National Health Laboratory Service (NHLS) at 
Groote Schuur Hospital, Cape Town. The investigators who performed the PCR testing 
were blinded to the IF or silver stain results.   
 
Data Analysis 
Statistical analysis was performed using statistical software Stata (version 10.0, 
StataCorp, Houston, USA). Continuous data was tested for normality using the Shapiro-
Wilk test. Detection rates of PCR were compared by Pearson’s chi-squared test and 
quantification results were compared by Wilcoxon rank-sum (Mann-Whitney) test. 
Paired analysis of continuous and binary variables was performed using t test and chi- 























212 children were enrolled (Table 1); 10 patients were excluded as there was 
insufficient respiratory sample left for PCR, thus 202 children were included in this 
analysis. Of these, 92 (46%) were male; the median (IQR) age was 3.3 (2.2 - 4.6) months. 
HIV status was determined in 200 (99%) patients, of whom 129 (65%) were HIV-
infected. Of the 71 (35%) HIV-uninfected children, 32 (45%) were HIV-exposed. Twenty-
seven (21%) of the 129 HIV-infected children were on cotrimoxazole prophylaxis at 
presentation. The median (IQR) CD4 percentage of HIV-infected children was 16.9 (10.1 
- 27.1)  
 
Table 1. Baseline characteristics of children admitted to hospital with suspected 





     (n = 202) 
Patients with positive PCR for 
PCP (n = 110) 
Male 92 (46%) 49 (45%) 
Median age, IQR, months 3.3 (2.2-4.6) 3.4 (2.7-3.9) 
HIV positive 129/200 (65%) 92/109 (84%)* 
Median CD4 percentage**, IQR, % 16.9 (10.1-27.1) 13.6 (9.0-18.0) 
Cotrimoxazole prophylaxis** 27 (21%) 10 (11%) 
* Odds-ratio OR, 7.9; 95% CI 3.9-16.3 (PCR positive vs. HIV positive); p < 0.0001 














PCR and IF on patient samples 
349 respiratory samples were obtained. One hundred and forty-seven (73%) children 
had paired samples consisting of a NPA with either a BAL or IS. Fifty-five children 
produced a single respiratory sample (Table 2). 
 





NPA+IS            NPA+BAL 
Total Samples 
NPA 36 92 55 183 
IS 8 92 - 100 
BAL 11 - 55 66 
Total Samples 55 184 110 349 
URT, upper respiratory tract; LRT, lower respiratory tract; NPA, nasopharyngeal aspirate; IS, induced sputum; BAL, bronchoalveolar 
lavage 
 
Real-time PCR performed on 349 respiratory samples detected P. jirovecii in 180 
specimens (52%) (Table 3). Of the 202 patients, 110 (54.5%) had one or more specimens 
positive by PCR. Overall, P. jirovecii DNA was detected in 37 of 66 (56%) BAL specimens, 
56 of 100 (56%) IS and 87 of 183 (48%) NPA. There was no significant difference 
between the detection by PCR on lower respiratory tract samples compared to NPA 

















Table 3. Quantitative PCR and Direct IF performed on 349 respiratory samples collected 
from 202 patients 
 
 TOTAL 
(n = 349) 
URT 
(n = 183 ) 
LRT 
(n = 166 ) 
OR (95% CI) 
Positive PCR 180 (52%) 87 (48%) 93 (56%) 0.71 (0.46 - 1.11) 
Positive IF 26 (7%) 4 (2%) 22 (13%) 0.15 (0.04 - 0.45) 
URT, upper respiratory tract; LRT, lower respiratory tract; OR, Odds-ratio; CI, confidence interval; PCR, polymerase chain reaction; IF, 
immunofluorescence 
 
In contrast, P. jirovecii was detected by IF in 26 (7%) of samples, consisting of 13 (50%) 
BAL, 9 (35%) IS and 4 (15%) NPA samples. All 26 IF- ositive samples were positive on 
PCR and thus no additional cases were detected using IF. The overall yield on upper 
tract samples was 48% (87/183) by PCR, as compared to the yield of 2% (4/183) by IF (p 
< 0.0001). For lower tract samples, the yield from PCR was 56% (93/166) compared to 
13% (22/166) by IF (p < 0.0001). 
 
P. jirovecii was also demonstrated on silver stain in 8 of the 25 (32%) BAL samples sent 
for analysis. All 8 were also PCR positive, and 3 were IF positive.  Of the 17 patients with 
a negative BAL silver stain, 5 (29%) were PCR-positive and 3 were also IF positive. 
 
Comparison of yield by PCR on paired upper and lower respiratory tract samples 
Of the 147 paired upper and lower respiratory tract samples, 70 pairs were concordant 














results. Of the discordant pairs, most were PCR positive on the lower tract sample but 
negative on the upper tract sample (Table 4). Overall, the detection from upper and 
lower specimens by PCR was similar with 81 of 147 (55%) lower respiratory tract 
samples positive by PCR vs. 73 of 147 (50%) NPA samples (OR, 1.4; 95% CI, 0.91-2.19). 
Only 8 (5%) additional cases were detected by PCR when performed on a lower 
respiratory tract sample compared to a NPA specimen (p = 0.11). Using a positive PCR 
result on a lower respiratory tract sample as a gold standard, the sensitivity, specificity, 
positive predictive value and negative predictive value for PCR on a NPA sample was 
86%, 95%, 96% and 85% respectively. 
 
Table 4. Real-time PCR results on paired upper and low r respiratory tract samples 
(n=147) 
 
 LRT Sample (IS/BAL) 
Positive 
LRT Sample (IS/BAL) 
Negative 
Total 
URT Sample (NPA) 
Positive 
70 (48%) 3 (2%) 73 (50%) 
URT Sample (NPA) 
Negative 
11 (7%) 63 (43%) 74 (50%) 
Total 81 66 147 
URT, upper respiratory tract; LRT, lower respiratory tract; NPA, nasopharyngeal aspirate; IS, induced sputum; BAL, bronchoalveolar 
lavage 
 














(IQR) organism load detected in NPA samples was significantly lower than that detected 
in lower respiratory tract samples [5.9 (5.4 - 6.7) log copies/ml compared to 6.6 (5.8 - 
7.5) log copies/mL; p = 0.0002).  
 
Control group 
Of the 30 children in the control group, 18 (60%) were male; the median (IQR) age was 
6.0 (4.0 – 12.0) months. HIV status was determined in 21 (70%) patients, of whom 2 
(10%) were HIV-infected, 6 (28%) were HIV-exposed and 13 (62%) were HIV-unexposed. 
Twenty-eight (93%) of 30 control samples were PCR-negative. The 2 PCR positive 
samples (both NPA samples), were from HIV-unexposed infants, younger than 6 months 





























This study found that real-time PCR has a much higher sensitivity than the current 
standard diagnostic test of IF, with more than double the number of children diagnosed 
with PCP using PCR. The different staining methods, namely IF and silver stain, against 
which PCR was compared, have variable reliability especially when used on a NPA. 
However, these staining methods are the current standards for diagnosis. When IF on 
lower tract samples was used as the reference standard, the sensitivity of the PCR assay 
was 100%. The large proportion of IF-negative, PCR-positive samples suggests that the 
sensitivity of IF is poor; and the PCR results are likely to reflect true positive cases of PCP 
as children had severe respiratory illness, in the context of a known risk factor for PCP. It 
is therefore difficult to comment on specificity of PCR, as there is no ‘gold standard’ for 
comparison. The increase in diagnostic yield using PCR occurred in both upper and 
lower respiratory specimens, but was especially marked in samples from the upper 
respiratory tract. Therefore, using current methods of detection, PCP may be 
substantially under-diagnosed, accounting for the relatively low laboratory confirmation 
rate in clinical studies of approximately 20%. [1, 3] 
 
A second advantage of PCR is that an upper respiratory tract specimen was as reliable as 
a lower respiratory tract specimen for diagnosis. This study provides good evidence that 
in children, a diagnosis of PCP can be reliably made using PCR on a specimen obtained 
non-invasively from the upper respiratory tract. Obtaining a NPA is much easier than 
performing sputum induction, and carries a lower risk of nosocomial transmission of 














including in primary care. The detection of organism in an upper respiratory tract 
sample may be explained by infection extending to these airways in severe disease or by 
organisms that are propelled to the upper airway during coughing. [15] 
 
A further advantage of PCR is the rapidity of the test, with results obtainable within 
hours. Children with PCP are often seriously ill with a rapidly progressive course, thus 
timely diagnosis allows early initiation of treatment, with potential reduction in 
mortality. The usual management for patients with clinically suspected PCP is empiric 
treatment with co-trimoxazole and corticosteroids. Corticosteroids have been reported 
to reduce mortality in HIV-infected adults with PCP when initiated early; thus rapid 
confirmation of the diagnosis is also useful for initiating early corticosteroid therapy, 
especially as there may be concern about the use of corticosteroids in other infections 
such as CMV pneumonitis. [22, 23] 
 
A potential difficulty with PCR is distinguishing colonization from disease due to P. 
jirovecii. The organism has been increasingly reported to colonize the airways of adults 
with underlying chronic obstructive airway disease, with such individuals forming the 
reservoir for infection of susceptible hosts. [24] Moreover, positive PCR results have been 
reported in BAL samples from adults without clinical PCP, HIV, or other infections. [25] 
However, in the context of a severely ill, immunocompromised child with diffuse 
pneumonia and hypoxia, as occurred in the study patients, it is likely that a positive PCR 
represents disease. In addition, P. jirovecii infection in young children with immune 
compromise usually results in primary infection, with resultant severe illness rather than 














the 30 control children, only 2 tested positive by PCR. These 2 positive samples may 
represent true infection or disease, as primary infection is very common in children with 
most infected within the first few years of life. A further explanation may be laboratory 
contamination. However, the molecular laboratory layout in our institution is designed to 
allow unidirectional work-flow with strict separation of all steps involved in the PCR 
process. The real-time PCR was performed in a closed system, with detection occurring 
on the same platform thus minimizing the risk of contamination.  
 
The quantitative results obtained in our study could not be accurately interpreted as 
data was not normalized by use of a reference gene as an internal control. 
Normalization would, in theory, control for variations in the extraction process, patient 
variability and inter-sample variability by accounting for the dilution factor in the BAL 
fluid. Unfortunately, although there is an awareness of the importance of this 
component in a quantitative PCR assay, there is still some debate about the choice of 
the most appropriate reference gene. [26] If normalization could be reliably performed, 
it may allow for more accurate estimation of colonization rates and perhaps the 
determination of cut-off values thus improving the specificity of the assay.  
 
Potential difficulties in achieving widespread implementation of PCR for PCP diagnosis 
include cost and the need for a specialized molecular laboratory, equipment, and 
personnel. However, much progress has been made in developing closed molecular 
amplification platforms for the diagnosis of TB at point-of-care facilities. Given the scale 
of the HIV pandemic and the substantial mortality associated with PCP particularly in 















In summary, this real-time PCR-based assay has a much higher sensitivity than current 
diagnostic tests and allows for the use of a NPA sample for reliable detection of P. 
jirovecii in children. PCR on a NPA should replace the traditional diagnostic method of IF 
or silver stain performed on lower respiratory tract samples. Widespread 
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PATIENT INFORMATION AND CONSENT FORM 
 
Pneumocystis jirovecii pneumonia in children – diagnosis & emergence of resistance 
 
You and your child are requested to participate in a medical research study that is being done at 
Red Cross Children’s hospital.  This study is being done by a team of researchers in the 
Department of Paediatrics and Child Health of the University of Cape Town. The following 
information will describe the study and your child’s role as a participant.  Please read this 
carefully and feel free to ask any questions. The study will be conducted according to the 




Your child has been hospitalised for a chest infection. This may be caused by a germ called 
Pneumocystis jirovecii which can cause a severe chest infection or pneumonia (PCP) in children.  
The aim of this study is to do a number of tests for PCP to investigate whether your child does 
have PCP.  Your child will be treated for PCP with a medicine called cotrimoxazole (Bactrim).   
Sometimes, other germs especially viruses can occur at the same time as PCP, causing a severe 
chest infection. Cytomegalovirus (CMV) is a germ that often causes infection with PCP.  We will 
also therefore check whether your child has any other germ in their chest or blood, as some of 
these germs must be treated with additional medicines. 
 
What is the reason for the study and how will it be done? 
 
The aim of this study is to find out the cause of your child’s chest problem, particularly to test for 
PCP.  In order to check for PCP, we will do a number of tests, which will be sent to the laboratory 
for testing for this germ. We will also do additional tests for other germs especially to test for a 
virus called cytomegalovirus (CMV). The tests that will be done as part of this study are: 
 
1) A sample of mucus from the chest or from the lungs (bronchoalveolar lavage, if 
your child is so ill that he/ she needs a tube to breathe) will be taken. To get a 
sample of mucus from the chest, a breathing treatment to open your child’s lungs 
will be given, after which your child will be nebulised with very salty water. After 














of salt water will be put down the breathing tube and then suctioned back. These 
tests are usually done in children who may have PCP and are part of the usual 
way in which we look for PCP in children with chest infections. The mucus will 
also be sent to check for CMV. This is the usual way in which we check for germs 
causing a bad chest infection 
2) A sample of mucus from the nose will be taken by doing a nose swab.  To do the 
nose swab we will put a few drops of salt water in the nostrils and then gently 
suction it out.  The mucus samples are sent to the laboratory to check for germs 
in the mucus. This will include checking for PCP and for CMV. A sample of the 
mucus specimens may also be stored, if there is mucus left over after testing for 
the germs. The stored mucus will be used should a better test for PCP become 
available in the future 
3) A blood test will be done to check if your child is making blood cells (antibodies) 
to protect him/ her against PCP. Less than half a teaspoonful of blood will be 
taken for this test. This test may be repeated during the time your child is in 
hospital 
4) A blood test will be taken to test for CMV. Less than half a teaspoonful of blood 
will be taken for this test. 
What does the study mean for your child? 
We will look at your child’s hospital folder for her/his medical information and results of tests 
that have been done.  Your child will receive the usual investigations and treatment in hospital; in 
addition, study tests as listed above will be done.  
What are the possible benefits to your child? 
From this study, we may be able to be more certain about whether your child has PCP or not, 
thus ensuring that he/ she gets the necessary treatment. We will also be more certain whether 
your child has CMV. Your child will be treated with a medicine for CMV if the tests show that CMV 
is causing his/ her illness. 
The study may also benefit other children with chest infections, as we hope it will help us to find 
the best test for PCP, which can then be used for other children who may have PCP.   
What are the possible risks to your child? 
This study poses very little risk to your child. Besides the usual blood tests, a small amount of 














CMV. Your child may have more coughing or develop a small amount of nose bleeding or get a 
tight chest when the nurse is obtaining a sample of mucus from his / her lungs. If your child 
develops a tight chest then we will give him / her a breathing treatment to open the chest. If your 
child develops nose bleeding, then we will push on the nose and apply ice to stop this. 
Confidentiality 
 
Your child’s study records will be kept confidential.  Neither you nor your child’s name will appear 




You may choose for your child to be in this study. If you choose not to be in the study then your 
child will get regular treatment for his/ her chest infection including treatment for PCP. Being in 
the study will not affect any other treatment that your child will receive.  
 
 
I have read and understood this form. My questions have been answered.  I voluntary consent to 
have my child participate. 
 
I, ____________________, the parent/ legal guardian of _____________________________ 
agree to allow her/him to participate in this study. 
 
 
Signed:  __________________ Witness:  __________________ 
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basic mechanisms with application to clinical material, will be welcomed. We aim to 
cover all areas of respiratory medicine (epidemiology, paediatrics, immunology, 
pharmacology, pathology, surgery and critical care) through publishing original papers, 
editorials, reviews, case reports and images. The priorities are originality and excellence.  
All submissions are subject to peer review. All papers that are potentially acceptable 
undergo statistical analysis. 
Submissions to Thorax, once peer reviewed, are discussed at the weekly editorial 
committee prior to decision. We aim to ensure a fair and independent peer review 
system and to publish articles which follow the highest ethical standards concerning 
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publishing original research in a BMJ Journal for a fee of 
£1,700(+VAT)/€2,515(+VAT)/$3,145.  
Article types and word counts 
 Original Research 
 Case Reports 
 Pulmonary Puzzles 
 Images in Thorax 
 Reviews 
 Letter to the editor (original research) 
 Correspondence 
 Editorials 
 Lung alerts 
 Supplements 
The word count excludes the title page, abstract, tables, acknowledgements and 















Original Research  
Full papers should follow the basic structure of abstract, introduction, methods, results, 
discussion, references, and tables and figures as appropriate. They should not normally 
exceed 250 words for the abstract, 3000 words for the content and include no more than 
35 references. There is an online data repository for extra information, tables, figures and 
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Manuscript format 
All manuscripts must be submitted via Bench>Press. 
 
All material submitted is assumed to be submitted exclusively to the journal unless the 
contrary is stated. Submissions may be returned to the author for amendment if 
presented in the incorrect format. 
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circumstances, Excel files can be uploaded as supplementary files; however, we advise 
against this as they will not be acceptable if your article is accepted for publication.  
 
Tables should be self-explanatory and the data they contain must not be duplicated in the 
















Authors are responsible for the accuracy of references cited: these should be checked 
against the original documents before the paper is submitted. It is vital that the 
references are styled correctly so that they may be hyperlinked.  
 
In the text  
References must be numbered sequentially as they appear in the text. References cited in 
figures or tables (or in their legends and footnotes) should be numbered according to the 
place in the text where that table or figure is first cited. Reference numbers in the text 
must be given in square brackets immediately after punctuation (with no word spacing) - 
for example, .[6] not [6].  
 
Where more than one reference is cited, separate by a comma - for example, [1, 4, 39]. 
For sequences of consecutive numbers, give the first and last number of the sequence 
separated by a hyphen - for example, [22-25]. References provided in this format are 
translated during the production process to superscript type, which act as hyperlinks 
from the text to the quoted references in electronic forms of the article. 
 
In the reference list  
References must be double spaced (numbered consecutively in the order in which they 
are mentioned in the text) in the [slightly modified] Vancouver style. Only papers 
published or in press should be included in the reference list. (Personal communications 
or unpublished data must be cited in parentheses in the text with the name(s) of the 
source(s) and the year. Authors should get permission from the source to cite 
unpublished data.) 
 
Punctuation of references must follow the [slightly modified] Vancouver style:  
12 Surname AB, Surname CD. Article title. Journal abbreviation. Year;Vol:Start page-End 
page.  
 
Use one space only between words up to the year and then no spaces. The journal title 
should be in italic and abbreviated according to the style of Medline. If the journal is not 
listed in Medline then it should be written out in full.  
 
Check journal abbreviations using PubMed.  
 
List the names and initials of all authors if there are 3 or fewer; otherwise list the first 3 
and add et al.  
 
















13 Koziol-Mclain J, Brand D, Morgan D, et al. Measuring injury risk factors: question 
reliability in a statewide sample. Inj Prev 2000;6:148-50.  
 
Chapter in book 
14 Nagin D. General deterrence: a review of the empirical evidence. In: Blumstein A, 
Cohen J, Nagin D, eds. Deterrence and incapacitation: estimating the effects of criminal 
sanctions on crime rates. Washington, DC: National Academy of Sciences 1978:95-139.  
 
Book 
(personal author or authors) (all book references should have specific page numbers) 
15 Howland J. Social norms and drunk driving countermeasures. In Graham JD, ed. 
Preventing automobile injury: new findings from evaluative research. Dover, MA: Auburn 
House Publishing Company 1988:163-96.  
 
Abstract/supplement 
16 Roxburgh J, Cooke RA, Deverall P, et al. Haemodynamic function of the carbomedics 
bileaflet prosthesis [abstract]. Br Heart J 1995;73 (sup l 2):P37.  
 
Electronic citations 
Basically, websites are referenced with their URL and access date, and as much other 
information is given as is available. Access date is important as websites can be updated 
and URLs change. The "date accessed" can be later than the acceptance date of the 
paper, and it can be just the month accessed. See the 9th edition of the AMA Manual of 
Style for further examples. 
 
electronic journal articles: 
Morse SS. Factors in the emergency of infectious diseases. Emerg Infect Dis 1995 Jan-
Mar;1(1). www.cdc.gov/nciod/EID/vol1no1/morse.htm (accessed 5 Jun 1998). 
 
Use as much information as the author gives. The volume/number information in the URL 
will take the user to the start of the individual document; ask the author to supply or 
confirm. Also ask authors to supply the date they accessed the file. 
 
Online First 
Each Online First article has a unique Digital Object Identifier (DOI). This should be 
included in all citations. 
 
BEFORE the article has appeared in an issue 














Sabin MA, Ford AL, Holly JMP, Hunt LP, Crowne EC, Shield JPH. Characterisation of 
morbidity in a UK, hospital based, obesity clinic. Arch Dis Child. Published Online First: 24 
October 2005. doi:10.1136/adc.2005.083485 
 
AFTER the article has appeared in an issue 
Use the citation format: 
Sabin MA, Ford AL, Holly JMP, Hunt LP, Crowne EC, Shield JPH. Characterisation of 
morbidity in a UK, hospital based, obesity clinic. Arch Dis Child 2006; 91:126-130 
doi:10.1136/adc.2005.083485 [published Online First: 24 October 2005]. 
 
Electronic Letters 
Author. Title of letter. Journal name Online [eLetter] Date of publication. url 
 
eg: Krishnamoorthy KM, Dash PK. Novel approach to transseptal puncture. Heart Online 
[eLetter] 18 September 2001. http://heart.bmj.com/cgi/eletters/86/5/e11#EL1 
 
Check your citation information using PubMed. 
 
Digital Object Identifiers (DOIs)  
DOIs are a unique string created to identify a piece of intellectual property in an online 
environment, particularly useful for articles which have been published online before 
appearing in print (therefore the article has not yet been assigned the traditional volume, 
issue and page number reference).  
 
The DOI is a permanent identifier of all versions of an article, whether raw manuscript or 
edited proof, online or in print. Thus the DOI should ideally be included in the citation 
even if you want to cite a print version of an article.  
 
How to cite articles before they have appeared in print 
To cite an electronic article that has not yet appeared in print please use the following 
citation format:  
1. Alwick K, Vronken M, de Mos T, et al. Cardiac risk factors: prospective cohort study. 
Ann Rheum Dis. Published Online First: 5 February 2004. doi:10.1136/ard.2003.001234  
 
How to cite articles once they have appeared in print 
Once the article has been printed the citation should also include the traditional year, 
volume and page numbers, as well as the DOI and original date of publication.  
1. Vole P, Smith H, Brown N, et al. Treatments for malaria: randomised controlled trial. 
Ann Rheum Dis 2003;327:765-8 doi:10.1136/ard.2003.001234 [published Online First: 5 















More comprehensive guidance about DOI's.  
 
PLEASE NOTE: RESPONSIBILITY FOR THE ACCURACY AND COMPLETENESS OF 
REFERENCES RESTS ENTIRELY WITH THE AUTHORS. 
Supplementary files 
You may submit supplementary material which may support the submission and review 
of your article. This could include papers in press elsewhere, published articles, 
appendices, video clips, etc. 
 
Online only material  
Additional figures and tables, methodology, references, video clips, raw data, etc may be 
published online only to supplement the printed article. If your paper exceeds the word 
count you should consider if any of the article could be published online only as a "data 
supplement". These files will not be copyedited or typeset.  
 
Bench>Press  
All supplementary data files should be uploaded to Bench>Press using the supplementary 
file section. These files are not converted to PDF but will be provided to reviewers and 
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UNIVERSITY OF CAPE TOWN , 
22 September 2009 
REC REF, 387/ 2009 
DrCMSamue1 
Medical Microbiology 
Dear Dr Samuel 
Health Sciences Faculty 
Research Ethics Committee 
Room E 52-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
Telephone [021]4066626 • Facsimile [021]406 6411 
e-mail: shuretta.thornas@Uct.ac.za 
PROJECT TITLE, MOLECULAR DIAGNOSIS OF PNEUMOCYSTIS JIROVECII 
PNEUMONIA IN ClflLDREN . 
. Thank you ·forsubmitting yOUl' study to the Rese:nth Ethics Ci:mlmiftee for r~ew. 
It is a pleasure to inform you that the E thics Committee has formally approved the above-mentioned srudy. 
Approval is granted for one year till the 30th September 2010. 
1. Amendment to 363/2006 is approved 
2. In future please set up a research registry for stored samples 
Please submit an annual progress report if the research continues beyond the expiry date. Please submit a brief 
swrunary of findings if you complete the study within the approval period so that we can close our file. 
Please note that the ongoing ethical conduct of the soody remains the responsibility of the principal 
investigator. 
Please quote the RE C. REF in aU your correspondence. 
Yours sincerely 
/!:f:£R~1:L 
P f CHAIRPERSON. HSF HUMAN ETHICS 



















lnsntunonal Kevtew .!:Soard (l.R..H) number. .l1{J:S(XXXJ1931:S 
'This serves to confum that the Univ.etSity. of Cape..Town.ll~ Ethics. Gommiu:ec:....compJies. [Q the E~ 
Standards fot Clinical Research with a new drug in patients. based on the Medical Research Council (MRC-
SA). Food and Drug Administration (FDA-USA), International Convention on Hannonisation Good Clinical 
Practice (ICH GCp) and Declaration of Helsinki guidelines. 
The Research Ethics Committee granting this approval is in compliance with the ICH Hannonised Tripartite 
Guidelines £6, Note fo, Gwdance on Good Clinic," P"ctice (CPMP / ICH/ 135/95) and FDA Code Feda.J 
Regulation Part 50, 56 and 312. 
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